

**Relyvrio (sod phenylbutyrate/taurursodiol) Prior Authorization Request Form** 



**Caterpillar Prescription Drug Benefit** Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION			
LAST NAME:	FIRST NAME:		
PHONE NUMBER:	DATE OF BIRTH:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
PATIENT INSURANCE ID NUMBER:			

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI DISCLOSURE AUTHORIZATION.PDF

MALE FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_\_\_

## PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY INITIATED:			
DURATION OF THERAPY (SPECIFIC DATES):					
Continued on payt page					

Continued on next page

© 2017 – 2022 by Magellan Rx Management, LLC. All Rights Reserved. Magellan Rx Management – Commercial Clients. CAT0295 5.1.2023







Relyvrio (sod phenylbutyrate/taurursodiol) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
	R MEDICATIONS FOR THIS CONDITION?	VES (if yos, complete below)		
<b>MEDICATION/THERAPY</b> (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
□ Amyotrophic Lateral Sclerosis (ALS) □ Other diagnosis:ICD-				
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	I: PLEASE PROVIDE ALL RELEVANT CLINIC	ALINFORMATION TO SUPPORT A		
Clinical Information:				
Initial Approval: Is this drug being prescribed to this patient as part of a treatment regimen specified within a sponsored clinical trial?  □ Yes □ No				
Ia prescriber a neurologist? 🗆 Yes 🛛 No				
Has the patient been diagnosed with clinically definite or probable ALS based on El Escorial revised criteria or Awaji criteria?  Yes  No (documentation required)				
Has the patient had a diagnosis of ALS for less than or equal to 18 months? 🗆 Yes 🛛 No (documentation required)				
Is the patient's percent-predicted forced vital capacity (%FVC) greater than or equal to 60%? <ul> <li>Yes</li> <li>No</li> <li>(documentation required)</li> </ul>				
Does the patient have retained functionality for most activities of daily living as indicated by an ALSFRS-R score of greater than or equal to 2 or better on each individual item of the ALS Functional Rating Scale – Revised (ALSFRS-R)? R)? Yes No (documentation required)				
<u>Renewal:</u> Has patient had a decline in their ALSFRS-R score of greater than 8 points during a 6-month treatment period? Yes 🛛 No Please provide documentation of ALSFRS-R score.				
Does patient have a cumulative score on the ALSFRS-R of $\leq$ 3? (documentation required of ALSFRS-R score required)? $\Box$ Yes $\Box$ No				
Is patient dependent on invasive ventilation or tracheostomy? 🗆 Yes 🛛 No				
Is prescriber a neurologist?  Yes No				

© 2017 – 2022 by Magellan Rx Management, LLC. All Rights Reserved. Magellan Rx Management – Commercial Clients. CAT0295 5.1.2023







**Relyvrio (sod phenylbutyrate/taurursodiol)** 



**Prior Authorization Request Form** 

**Caterpillar Prescription Drug Benefit** Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group, or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

## FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn:CP-4201 P.O.Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909



